- Home
- NTCT vs IMCR Comparison
NTCT vs IMCR Comparison
Compare NTCT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTCT
- IMCR
- Stock Information
- Founded
- NTCT 1984
- IMCR 2008
- Country
- NTCT United States
- IMCR United Kingdom
- Employees
- NTCT N/A
- IMCR N/A
- Industry
- NTCT EDP Services
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTCT Technology
- IMCR Health Care
- Exchange
- NTCT Nasdaq
- IMCR Nasdaq
- Market Cap
- NTCT 1.6B
- IMCR 1.8B
- IPO Year
- NTCT 1999
- IMCR 2021
- Fundamental
- Price
- NTCT $25.35
- IMCR $33.42
- Analyst Decision
- NTCT Buy
- IMCR Buy
- Analyst Count
- NTCT 2
- IMCR 8
- Target Price
- NTCT $29.00
- IMCR $57.00
- AVG Volume (30 Days)
- NTCT 540.6K
- IMCR 288.3K
- Earning Date
- NTCT 10-23-2025
- IMCR 11-05-2025
- Dividend Yield
- NTCT N/A
- IMCR N/A
- EPS Growth
- NTCT N/A
- IMCR N/A
- EPS
- NTCT 1.02
- IMCR N/A
- Revenue
- NTCT $834,861,000.00
- IMCR $356,145,000.00
- Revenue This Year
- NTCT $4.15
- IMCR $29.67
- Revenue Next Year
- NTCT $2.42
- IMCR $11.12
- P/E Ratio
- NTCT $24.95
- IMCR N/A
- Revenue Growth
- NTCT 5.29
- IMCR 26.78
- 52 Week Low
- NTCT $18.12
- IMCR $23.15
- 52 Week High
- NTCT $27.89
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- NTCT 62.54
- IMCR 44.20
- Support Level
- NTCT $24.94
- IMCR $35.33
- Resistance Level
- NTCT $25.82
- IMCR $36.76
- Average True Range (ATR)
- NTCT 0.48
- IMCR 1.46
- MACD
- NTCT 0.01
- IMCR -0.12
- Stochastic Oscillator
- NTCT 69.68
- IMCR 24.65
About NTCT NetScout Systems Inc.
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.